Is CJC-1295 legal? the comprehensive answer.

Current US FDA status, in straightforward terms

CJC-1295 is not an FDA-approved drug. There is no completed New Drug Application, no approved label, no agency-approved indication, and no pharmacy can dispense it as a finished pharmaceutical. The ConjuChem development program reached Phase 2 trials in HIV-associated lipodystrophy and was discontinued without registration.

Beyond drug approval, the question that matters for access is whether licensed compounding pharmacies can prepare CJC-1295 from bulk drug substance. That question is governed by the FDA’s bulk drug substance category lists. Three categories matter:

• Category 1: Substances that may be used by 503A compounding pharmacies under appropriate conditions. This is the legitimate compounding lane.
• Category 2: Substances that 503A pharmacies are not currently permitted to use, typically because of insufficient safety data or unresolved identity-and-characterization concerns.
• Category 3: Substances under active evaluation, with no final determination yet.

Before April 15, 2026, CJC-1295 sat on Category 2. That meant 503A compounding pharmacies could not legally prepare CJC-1295 for patient use. The reasons related to the absence of completed pivotal trials, the identity-and-characterization questions raised by the dual DAC/non-DAC forms, and the broader skepticism the agency applied to compounded peptides with limited human data.

On April 15, 2026, FDA reorganized the bulk drug substance lists. CJC-1295 was removed from Category 2. It was not placed on Category 1. The molecule now sits in a gap, with no formal classification, pending review by the Pharmacy Compounding Advisory Committee (PCAC). That gap is the entire source of the current regulatory uncertainty.

How CJC-1295 ended up where it did

The trajectory matters because it explains why the current state is so ambiguous.

1. 2004 to 2006: ConjuChem develops CJC-1295 with DAC and runs the Phase 1 trial published by Teichman and colleagues in 2006. The trial demonstrates sustained GH and IGF-1 elevation for roughly a week from a single subcutaneous dose.
2. Late 2000s: ConjuChem advances CJC-1295 into Phase 2 trials for HIV-associated lipodystrophy. The rationale parallels tesamorelin, a separately developed GHRH analog that would receive FDA approval for that indication in 2010.
3. Early 2010s:ConjuChem winds down. The CJC-1295 development program does not pass to a successor sponsor that pursues a registrational program. The compound’s pharmaceutical-development trajectory effectively ends.
4. Mid 2010s onward: CJC-1295 appears as a research chemical sold by overseas vendors, then as a compounded peptide offered by a subset of US compounding pharmacies under the assumption that it could be prepared from bulk drug substance.
5. Late 2010s and early 2020s: FDA places CJC-1295 on Category 2, citing insufficient safety data, identity-and-characterization questions, and the absence of completed pivotal trials. 503A compounding becomes formally prohibited.
6. April 15, 2026: FDA reorganizes the bulk drug substance lists. CJC-1295 is removed from Category 2 but not placed on Category 1, pending PCAC review.

Two things explain why this is genuinely unresolved. First, the molecule has more peer-reviewed Phase 1 data than most peptides in the FDA regulatory ambiguity, because the Teichman 2006 trial was published in a major endocrinology journal. Second, the absence of completed pivotal trials, the ConjuChem-to-nowhere development trajectory, and the dual-form identity-and-characterization issue (DAC vs non-DAC, with both sold under the same name) are real concerns that the FDA has not formally resolved.

The compounding implication: 503A cannot compound Cat 2

One detail that needs to be precise: while CJC-1295 was on Category 2, 503A compounding pharmacies could not legally prepare it. There is no workaround for that. PepScribe’s pharmacy standard is 503A-only, and 503A pharmacies cannot compound a Category 2 substance regardless of clinician interest, patient demand, or claimed pharmacy expertise. The Category 2 designation, while it was in effect, was a hard stop.

Some online content blurs this by referring to compounding pharmacies that continued offering CJC-1295 during the Category 2 period. Those operations were either based on misreading of the regulations, on a willingness to operate under enforcement risk, or in the case of overseas operations, in jurisdictions outside FDA reach. None of those routes are appropriate for a US-based 503A-only pharmacy operating within the regulatory framework.

After the April 2026 reshuffle, the question becomes more nuanced. With CJC-1295 no longer on Category 2, the prohibition on 503A compounding is arguably lifted. Some 503A pharmacies have started compounding CJC-1295 on that interpretation. The interpretation is plausible. It is also not formally settled. Until PCAC review concludes and FDA issues a final classification, compounding occurs in a gap where the legal picture is genuinely uncertain.

PepScribe’s position on this is conservative: transitional GHRH analogs like CJC-1295 are evaluated in consultation, not sold as commercial products, until the regulatory classification is settled. This is not a comment on whether CJC-1295 is a useful drug. It is a comment on what responsible commercial behavior looks like during a period of regulatory ambiguity.

Gray-market risks: purity, sterility, dosing accuracy

Vials labeled “CJC-1295” are widely available from research chemical suppliers, overseas pharmacies, and underground markets. The risks of these sources are not theoretical. They are the same risks that show up across the gray-market peptide landscape, with one additional layer that CJC-1295 introduces.

Purity and identity

Without pharmaceutical-grade manufacturing oversight, products sold as CJC-1295 may contain truncated peptide chains, partially synthesized sequences, the wrong variant entirely, or a different peptide altogether. Independent third-party testing of gray-market peptide samples has repeatedly found mislabeled or substandard products across the broader peptide market. CJC-1295 is not exempt from this pattern.

The dual-form issue (DAC vs non-DAC) compounds the identity problem. Vials sometimes mix up which variant is in the bottle, particularly when sourced through informal channels. The DAC and non-DAC forms have very different pharmacokinetic profiles, and a patient expecting non-DAC short-acting pharmacology who receives DAC long-acting pharmacology will experience continuous receptor stimulation for days when they expected hours. The dosing implications are not minor.

Sterility

Injectable peptides require strict sterility controls. Bacterial endotoxins are particularly problematic because they survive sterilization steps that kill bacteria themselves. Gray-market vials lack the validated sterility processes that licensed pharmaceutical and 503A compounding facilities operate under. The risk of injection-site infection, abscess, or systemic infection from non-sterile preparations is real and well-documented across the gray-market peptide world.

Dosing accuracy, with a CJC-1295-specific twist

Gray-market vials are often labeled by mass (for example, “5 mg per vial”) but the actual peptide content can deviate substantially from the label claim, in either direction. Underfilling means an underdose; overfilling means an overdose. For most peptides this is bad enough.

For CJC-1295 with DAC specifically, the consequences of a wrong dose persist for days, not hours. A non-DAC peptide that you mis-dosed at 3 PM clears by bedtime; you got an unintentional acute exposure and the system recovers overnight. A DAC peptide that you mis-dosed at 3 PM is still in your system a week later, with sustained GH and IGF-1 elevation, with no easy way to speed clearance, and with whatever endocrine consequences follow from a week-long unintended dose. The long half-life that makes CJC-1295 with DAC attractive from an adherence perspective also makes dosing errors much more consequential.

This is one of the strongest arguments against gray-market sourcing for the DAC variant in particular. The margin for error is much smaller, the consequences last much longer, and the ability to reverse course is effectively zero.

The “research use only” legal disclaimer

Most gray-market peptide vendors label their products “for research use only” or “not for human consumption.” This is a legal disclaimer that allows the vendor to sell substances outside the pharmaceutical regulatory framework. It does not create a legitimate self-administration pathway, it does not protect the buyer, and it does not imply that the product meets any quality standard. It is a litigation shield, not a quality assurance.

International picture: UK, Canada, Australia, EU

CJC-1295 has never received marketing approval in any major regulatory jurisdiction. The picture across the most-asked-about countries:

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) has not approved CJC-1295 as a medicine. It cannot be legally sold as a medicine or health product in the UK. Research chemical sourcing exists in a legal gray area similar to the US gray market, but UK compounding regulations do not provide a 503A-equivalent pathway for unapproved peptides. Therapeutic access through legitimate medical channels is essentially closed.

Canada

Health Canada has not approved CJC-1295 as a drug, and it does not appear in the Drug Product Database or the Licensed Natural Health Products Database. Canadian compounding pharmacies operate under provincial regulations, and preparation of unapproved peptides is generally more restricted than under US 503A rules. Personal-use importation from international sources may violate the Food and Drugs Act, particularly when the substance is represented as therapeutic.

Australia

The Therapeutic Goods Administration (TGA) takes a notably strict approach to peptides. CJC-1295 is not on the Australian Register of Therapeutic Goods (ARTG). The TGA has specifically targeted unapproved peptide importation and sale, and Australian Border Force has seized peptide shipments at the border. Compounding pharmacies in Australia operate under state and territory regulations and generally cannot prepare substances that are not TGA-approved without specific exemptions. Australia’s regulatory environment is among the most restrictive globally for peptide access.

European Union

The European Medicines Agency (EMA) has not approved CJC-1295. Tesamorelin, a structurally related GHRH analog, has FDA approval for HIV-associated lipodystrophy in the United States, but its EMA application for the same indication was withdrawn before approval. CJC-1295 itself does not have approval anywhere in the EU, and individual member states’ rules on compounding and personal-use importation vary, with most operating closer to the Australian model than the US 503A model.

International takeaway

No major regulatory jurisdiction has approved CJC-1295 for therapeutic use. The compounding-pharmacy lane that defines the US transitional is largely absent in other countries. If you are researching CJC-1295 from outside the United States, the practical reality is that legal therapeutic access is essentially closed, and gray-market sourcing carries the standard purity, sterility, and identity risks plus customs and importation exposure.

WADA prohibition: CJC-1295 is banned in competitive sport

CJC-1295 is prohibited by the World Anti-Doping Agency under Section S2 of the Prohibited List, which covers peptide hormones, growth factors, related substances, and mimetics. CJC-1295 is named explicitly under S2.2.4, the Growth Hormone Releasing Factors subcategory, alongside other GHRH analogs including sermorelin and tesamorelin. Athletes subject to WADA jurisdiction cannot use it.

Key points for athletes at any level:

• The ban applies in-competition and out-of-competition. There is no off-season exception for peptide hormones and growth factors.
• Therapeutic Use Exemption is essentially unavailable. Because CJC-1295 has no approved therapeutic indication anywhere in the world, a Therapeutic Use Exemption application would have nothing to point to. Tesamorelin (FDA-approved for HIV lipodystrophy) is the only GHRH-analog drug class member with an approved indication, and even that is narrowly scoped.
• Detection methods exist. Anti-doping laboratories have developed and continue to refine detection methods for synthetic GH-secretagogues. The long half-life of the DAC form, in particular, leaves a longer detection window than short-acting GH-axis agents.
• Sanctions are severe. A positive test for a WADA-prohibited substance can result in multi-year competition bans, loss of titles and medals, financial penalties, and reputational damage that does not fade.
• The prohibition extends beyond elite sport. Many collegiate, amateur, and professional sports organizations adopt the WADA Prohibited List or maintain parallel lists that include CJC-1295.

If you are a competitive athlete at any level, consult the current WADA Prohibited List directly (wada-ama.org/en/prohibited-list) and your sport’s anti-doping authority before considering any GH-axis peptide.

Possession vs sale: a useful legal distinction

Patients often conflate three different questions: can I be arrested for having this, can someone be arrested for selling this, and can I get a doctor to prescribe this through a regulated pharmacy? They are not the same questions, and they do not have the same answers.

• Possession in the United States: CJC-1295 is not on any schedule of the Controlled Substances Act. Simple possession of CJC-1295 is unlikely to result in criminal charges in most US contexts, although this depends on jurisdiction and surrounding facts. This is not the same as “legal” in any practical sense.
• Sale in the United States: Selling CJC-1295 as a finished pharmaceutical product without FDA approval, or marketing it as a dietary supplement, both fall outside the regulatory framework. The FDA has taken enforcement action against vendors selling peptides with research-use disclaimers when the marketing context indicated intent for human consumption.
• Compounding in the United States: 503A pharmacy compounding is currently in the gap described above, with some pharmacies compounding CJC-1295 on the post-April-2026 no-longer-Cat-2 interpretation, but no formal Cat 1 placement yet. This is the most important question for patients seeking legitimate access, and it has the most uncertain answer.
• Personal importation: US personal-use importation of unapproved drugs operates under FDA enforcement discretion, which is narrower than many online vendors imply. Customs seizure of peptide shipments is a real and recurring outcome.

The practical answer is that “legal” for CJC-1295 means different things at different levels of the supply chain. The clearest path to legitimate access is through a licensed clinician working with a 503A pharmacy operating within the current regulatory framework, with all the ambiguity that the current framework carries.

What reclassification would require

A clean Cat 1 placement for CJC-1295 would require FDA to formally evaluate the molecule against the criteria the agency uses for that designation. Those criteria typically include:

• Identity and characterization: The substance must be well-characterized chemically, with reference standards available, and methods established for verifying identity in bulk drug substance. The DAC vs non-DAC distinction complicates this because the bulk-drug-substance form needs to be specified.
• Safety data: Sufficient safety information to support compounding for the intended use, which for CJC-1295 is currently limited to the Phase 1 record plus extrapolation from related GHRH-analog drugs.
• PCAC review: The Pharmacy Compounding Advisory Committee provides a formal recommendation to FDA on whether a substance should be on Category 1.
• Federal Register publication: Any final classification decision is published in the Federal Register, which is the official journal of the US federal government and the formal vehicle for regulatory action.

The path from the current state to Cat 1 is therefore not automatic. It requires PCAC review, formal agency evaluation, and Federal Register publication. The path to a clean Cat 2 reinstatement is also possible, if PCAC reviews the molecule and concludes the data does not support compounding. There is a third possibility, which is that the classification gap simply persists for an extended period, leaving 503A pharmacies and clinicians to make their own judgment calls in the meantime.

For patients trying to plan around this uncertainty, the practical advice is to assume the regulatory picture may shift in either direction over the coming year, and to choose pharmacies and clinicians who will respond appropriately if classification changes. PepScribe’s position is that current FDA classification, in either direction, is not the right state for peptide-direct commercial marketing. Consultation-first is the appropriate model until the regulatory state is settled.

Currently available alternatives in the same drug class

For patients exploring GHRH-axis support who want to work within a clean regulatory state, sermorelin is the legitimate path. Sermorelin is the unmodified GHRH(1-29) parent compound, the molecule that CJC-1295 was engineered from. It is a Tier 1 peptide on PepScribe’s commercial roster, with current Cat 1 status, available through licensed compounding pharmacies under clinician prescription.

The reasons sermorelin works as a sermorelin-for-CJC-1295 substitute:

• Same receptor target: Sermorelin and CJC-1295 both bind the pituitary GHRH receptor and trigger the same downstream signaling cascade. The mechanism is the same; the engineering around half-life is what differs.
• Established clinical record: Sermorelin had FDA approval for pediatric GHD before its 2008 voluntary withdrawal for commercial reasons unrelated to safety, and decades of clinical experience inform current dosing and monitoring practice.
• Pulsatile pharmacokinetics: Sermorelin’s short half-life produces discrete GH pulses that mimic physiological GHRH release, which some clinicians regard as the preferable receptor-exposure pattern.
• Cat 1 status: Licensed 503A compounding pharmacies can legally prepare sermorelin. The supply chain is legitimate, the regulatory state is clean, and the pharmacy has the same accountability as for any compounded medication.
• Available commercially: PepScribe offers sermorelin as a Tier 1 commercial product. A licensed clinician evaluates the patient, prescribes if appropriate, and a 503A pharmacy fills the prescription.

Sermorelin is not a perfect drop-in for every patient considering CJC-1295. The pharmacokinetic profiles are different, sermorelin requires more frequent dosing, and the convenience advantage of the once-weekly DAC form is real. But for most GH-axis goals in healthy adults working within a legitimate clinical framework, sermorelin offers the combination of a well-characterized mechanism, a clean regulatory state, a legitimate supply chain, and a real safety record that CJC-1295 currently does not.

If you are evaluating GHRH-axis support and the regulatory uncertainty around CJC-1295 is part of why you ended up on this page, sermorelin is the answer to that question. It is the same drug class, the same receptor mechanism, the same family of clinical applications, and an entirely different regulatory state.

Summary table: where CJC-1295 stands

CJC-1295 occupies a regulatory state that does not have a clean answer in any jurisdiction. In the United States, the April 2026 reshuffle moved it off the prohibited list without placing it on the permitted list, leaving a gap that 503A pharmacies and clinicians are interpreting individually. In every other major jurisdiction, the answer is closer to no clean access at all. WADA prohibits it for competitive sport globally.

For now, the most responsible course of action is to stay informed about the pending PCAC review, consult licensed healthcare providers, and consider whether the established Cat 1 alternative, sermorelin, addresses the underlying clinical goal that brought you to CJC-1295 in the first place.